Company intelligence / Profile preview
ST Phi Therapeutics
Seattle, Washington, United Statesen.stphibio.com ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
ST Phi Therapeutics develops engineered cell therapies using its proprietary CNK Universal T-cell platform. The company has demonstrated long-term safety and efficacy in liver cancer, neuroblastoma, breast cancer patients, and steroid-refractory GVHD. Its lead programs are in early clinical or preclinical stages targeting a range of cancers and autoimmune diseases.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Cell therapy (including Universal CAR-T)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on ST Phi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST Phi Therapeutics.